Dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis

A technology of oxymetazoline hydrochloride and oxymetazoline acid, which is applied in the field of medicine, can solve problems such as complex compatibility and limited application, achieve strong adhesion, restore normal function, and improve nasal cavity comfort

Active Publication Date: 2020-03-27
深圳大佛药业股份有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above-mentioned pharmaceutical composition for the treatment of rhinitis has complex compatibility, which limits its application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis
  • Dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis
  • Dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1, a kind of two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis

[0040] The two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis is provided with two conjoined spray chambers, and the aqueous solution containing oxymetazoline hydrochloride and the Glycoside emulsion.

[0041] The aqueous solution containing oxymetazoline hydrochloride comprises the following components and mass percentages thereof: 0.01% oxymetazoline hydrochloride, 0.5% sodium chloride, 0.4% functional auxiliary agent, and 99.09% purified water; the functional auxiliary agent consists of Chitooligosaccharide and sodium alginate are composed in a mass ratio of 6:3; the average molecular weight of the chitooligosaccharide is 1000.

[0042] The preparation method of the aqueous solution containing oxymetazoline hydrochloride is:

[0043] Add oxymetazoline hydrochloride to purified water, stir until completely d...

Embodiment 2

[0051] Embodiment 2, a kind of two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis

[0052] The two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis is provided with two conjoined spray chambers, and the aqueous solution containing oxymetazoline hydrochloride and the Glycoside emulsion.

[0053] The aqueous solution containing oxymetazoline hydrochloride comprises the following components and mass percent thereof: 0.02% oxymetazoline hydrochloride, 1% sodium chloride, 0.6% functional auxiliary agent, and 98.38% purified water; the functional auxiliary agent consists of Oligochitosan and sodium alginate are composed at a mass ratio of 8:1; the average molecular weight of the oligochitosan is 2500.

[0054] The preparation method of the aqueous solution containing oxymetazoline hydrochloride is:

[0055] Add oxymetazoline hydrochloride to purified water, stir until completely dissolved, add functi...

Embodiment 3

[0063] Embodiment 3, a kind of two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis

[0064] The two-chamber nasal spray containing oxymetazoline hydrochloride for the treatment of rhinitis is provided with two conjoined spray chambers, and the aqueous solution containing oxymetazoline hydrochloride and the Glycoside emulsion.

[0065] The aqueous solution containing oxymetazoline hydrochloride comprises the following components and mass percentages thereof: 0.012% oxymetazoline hydrochloride, 0.7% sodium chloride, 0.5% functional auxiliary agent, and 98.788% purified water; the functional auxiliary agent consists of Chitooligosaccharide and sodium alginate are composed in a mass ratio of 7:2; the average molecular weight of the chitooligosaccharide is 1500.

[0066] The preparation method of the aqueous solution containing oxymetazoline hydrochloride is:

[0067] Add oxymetazoline hydrochloride to purified water, stir until completely...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis. The dual-cavitynasal spray containing oxymetazoline hydrochloride and used for treating rhinitis is provided with two connected spraying cavities, wherein an aqueous solution containing oxymetazoline hydrochloride and emulsion containing baicalin are respectively loaded in the two connected spraying cavities, and the aqueous solution containing oxymetazoline hydrochloride comprises oxymetazoline hydrochloride, sodium chloride, a functional auxiliary agent and purified water. The dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis is clear in composition and high in safety, and has favorable wetting effects on nasal mucosa, the comfortable degree of the nasal cavity is notably increased, and normal functions of the nasal cavity can be restored. In addition, compared with a conventional nose drop, the dual-cavity nasal spray containing oxymetazoline hydrochloride and used for treating rhinitis provided by the invention is more excellent in respects of quick activity and persistence for rhinitis, is free from side effects and favorable in compliance, and has favorable treatment effects on rhinitis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a two-chamber nasal spray containing oxymetazoline hydrochloride for treating rhinitis. Background technique [0002] The nasal cavity is located at the forefront of the respiratory tract. It has the functions of humidifying, warming and filtering the inhaled air. It is the first line of defense of the respiratory system and one of the organs most susceptible to infection. When inflammation enters the human body, the lower respiratory tract and related The only way for the spread of adjacent organs. In recent years, due to reasons such as air pollution, global warming, sudden temperature changes, bacterial virus infection, exposure to allergens, and decreased body resistance, the incidence of various nasal inflammations is on the rise. [0003] Rhinitis refers to the inflammation of nasal mucosa and submucosal tissue, and its manifestations are various. From the pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/12A61K31/4174A61K31/7048A61K31/734A61K31/722A61K47/34A61K47/24A61P11/02A61P37/08
CPCA61K9/0043A61K9/12A61K31/4174A61K31/7048A61K31/722A61K31/734A61K47/24A61K47/34A61P11/02A61P37/08A61K2300/00
Inventor 杨瑞雄
Owner 深圳大佛药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap